Compare Stocks

→ See this before next week's Fed meeting (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALSE Alseres Pharmaceuticals	$0.01	$0.01	$0.01 ▼ $0.01	N/A	0.15	N/A	N/A
MTST MetaStat		$0.00	$0.00 ▼ $0.08	N/A	N/A	N/A	N/A
OREXQ Orexigen Therapeutics	$0.01 +35.9%	$0.01	$0.00 ▼ $0.16	$100K	4.98	80,439 shs	60,300 shs
PZRXQ PhaseRx	$0.00	$0.00	$0.00 ▼ $0.00	N/A	-0.28	N/A	N/A
WDBG Woodbrook Group	$0.01	$0.01	$0.01 ▼ $0.01	$67K	2.78	N/A	N/A

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALSE Alseres Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-50.00%
MTST MetaStat	0.00%	0.00%	0.00%	0.00%	0.00%
OREXQ Orexigen Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
PZRXQ PhaseRx	0.00%	0.00%	0.00%	0.00%	+100.00%
WDBG Woodbrook Group	0.00%	0.00%	0.00%	0.00%	+242.86%

Mysterious Gold Leverage Just Announced (Ad)

World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.

Find out what it is and see how you can get in with just a few dollars.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALSE Alseres Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MTST MetaStat	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OREXQ Orexigen Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PZRXQ PhaseRx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
WDBG Woodbrook Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALSE Alseres Pharmaceuticals	N/A	N/A	N/A	N/A
MTST MetaStat	N/A	N/A	N/A	N/A
OREXQ Orexigen Therapeutics	N/A	N/A	N/A	N/A
PZRXQ PhaseRx	N/A	N/A	N/A	N/A
WDBG Woodbrook Group	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALSE Alseres Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
MTST MetaStat	N/A	N/A	N/A	N/A	N/A	N/A
OREXQ Orexigen Therapeutics	$33.71M	0.00	N/A	N/A	N/A	∞
PZRXQ PhaseRx	N/A	N/A	N/A	N/A	N/A	N/A
WDBG Woodbrook Group	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALSE Alseres Pharmaceuticals	N/A	N/A	∞	N/A	N/A	N/A	N/A	N/A
MTST MetaStat	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OREXQ Orexigen Therapeutics	-$24.52M	N/A	∞	N/A	N/A	N/A	N/A	N/A
PZRXQ PhaseRx	N/A	N/A	∞	N/A	N/A	N/A	N/A	N/A
WDBG Woodbrook Group	N/A	N/A	∞	N/A	N/A	N/A	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALSE Alseres Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MTST MetaStat	N/A	N/A	N/A	N/A	N/A
OREXQ Orexigen Therapeutics	N/A	N/A	N/A	N/A	N/A
PZRXQ PhaseRx	N/A	N/A	N/A	N/A	N/A
WDBG Woodbrook Group	N/A	N/A	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
ALSE Alseres Pharmaceuticals	N/A
MTST MetaStat	N/A
OREXQ Orexigen Therapeutics	N/A
PZRXQ PhaseRx	N/A
WDBG Woodbrook Group	N/A

Insider Ownership

Company	Insider Ownership
ALSE Alseres Pharmaceuticals	8.94%
MTST MetaStat	8.50%
OREXQ Orexigen Therapeutics	13.30%
PZRXQ PhaseRx	44.69%
WDBG Woodbrook Group	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ALSE Alseres Pharmaceuticals	3	N/A	N/A	Not Optionable
MTST MetaStat	6	N/A	N/A	Not Optionable
OREXQ Orexigen Therapeutics	N/A	18.89 million	N/A	Not Optionable
PZRXQ PhaseRx	10	N/A	N/A	Not Optionable
WDBG Woodbrook Group	30	9.29 million	N/A	Not Optionable

OREXQ, WDBG, MTST, PZRXQ, and ALSE Headlines

No headlines for this company have been tracked by MarketBeat.com

Media Sentiment Over Time

Company Descriptions

Alseres Pharmaceuticals

OTCMKTS:ALSE

Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

MetaStat

OTCMKTS:MTST

MetaStat, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes MetaSite Breast and MenaCalc platforms. The MetaSite Breast test measures the process of systemic metastasis and is intended for early stage breast cancer patients. The MenaCalc, a platform of diagnostic assays, based on the measurement of the balance of the Mena protein isoforms, is broadly applicable in solid epithelial-based cancers, including breast, prostate, lung and colorectal. The company was founded by Warren C. Lau in July 2009 and is headquartered in Boston, MA.

Orexigen Therapeutics

OTCMKTS:OREXQ

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

PhaseRx

OTCMKTS:PZRXQ

PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.

Woodbrook Group

OTCMKTS:WDBG

Woodbrook Group Holdings Inc. provides investment and strategic planning advisory services. It offers services in the areas of portfolio management, mid and long term investment management, alternative investments, lump sum investments, education fee planning, wealth planning, retirement planning, structured product building, and qualifying recognized overseas pension scheme and financial review. The company is headquartered in Limassol, Cyprus.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial